Last reviewed · How we verify
Biomatrix drug eluting stent
A drug-eluting stent that releases an active pharmaceutical agent to prevent restenosis (re-narrowing) of coronary arteries after angioplasty.
A drug-eluting stent that releases an active pharmaceutical agent to prevent restenosis (re-narrowing) of coronary arteries after angioplasty. Used for Coronary artery disease requiring percutaneous coronary intervention, Prevention of in-stent restenosis in coronary arteries.
At a glance
| Generic name | Biomatrix drug eluting stent |
|---|---|
| Also known as | Biomatrix drug eluting stent (Biosensors,Newport Beach,USA) |
| Sponsor | Seoul National University Bundang Hospital |
| Drug class | Drug-eluting stent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
The Biomatrix stent is a bare-metal stent platform coated with a bioabsorbable polymer matrix that elutes an anti-proliferative drug (typically a limus-class agent) to inhibit smooth muscle cell proliferation and neointimal hyperplasia. The polymer coating gradually degrades, allowing sustained drug release over several months to reduce the risk of in-stent restenosis while minimizing long-term inflammatory response.
Approved indications
- Coronary artery disease requiring percutaneous coronary intervention
- Prevention of in-stent restenosis in coronary arteries
Common side effects
- In-stent restenosis
- Stent thrombosis
- Myocardial infarction
- Target lesion revascularization
Key clinical trials
- The OCT SORT-OUT VIII Study (NA)
- Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice
- ALPHA LONG Study- BioMatrix AlphaTM Stent Study in Patients With CAD (NA)
- Sort Out XI - Combo Stent Versus BioMatrix Alpha Stent (NA)
- STACCATO: Stent sTrut Apposition and Coverage in Coronary ArTeries: an Optical Coherence Tomography (OCT) Study (NA)
- Evaluation of Effectiveness and Safety of BIOMATRIX Stent (IRIS-BIOMATRIX)
- e-BioMatrix 6 Month DAPT France
- Optical Coherence Tomography Evaluation of a Biodegradable Polymer-based Drug-eluting Stent
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biomatrix drug eluting stent CI brief — competitive landscape report
- Biomatrix drug eluting stent updates RSS · CI watch RSS
- Seoul National University Bundang Hospital portfolio CI